

**Table S1.** Clinical characteristics of the validation cohort of SSc patients ( $n = 29$ ).

Clinical Features	SSc Cohort $n = 29$
Age at inclusion, mean $\pm$ SD, y	60.3 (13.3)
Female sex	22 (75.9)
Disease duration, median, IQR, y	1.0 (6.9)
Skin involvement	
Limited	21 (72.4)
Diffuse	5 (17.2)
Sine sclerosis	3 (10.3)
Antibody	
Centromere	18 (62.1)
Topoisomerase I	6 (20.7)
RNA polymerase III	1 (3.4)
Other (Ku, Pm-ScL)	2 (6.9)
ANA only	2 (6.9)
Digital ulcers	11 (37.9)
ILD	11 (37.9)
Pulmonary hypertension	2 (6.9)
Immunosuppressive therapy	0
Creatinine, median, IQR, $\mu\text{mol/L}$	77 (26)
CRP median, IQR, $\text{mg/L}$	2.0 (3.0)
sIL2r, median, IQR, $\text{U/mL}$	453 (417)
dp-ucMGP, median, IQR, $\text{pmol/L}$	589 (370)
CVD at baseline	5 (17.2)

Data are presented as numbers (%) unless otherwise indicated. IQR: interquartile range; ILD: interstitial lung disease; ANA: anti-nuclear antibodies; CRP: c-reactive protein. sIL2r: soluble interleukin 2 receptor. Dp-ucMGP: Dephosphorylated and uncarboxylated Matrix Gla Protein. ¥ Defined as the date of the first non-Raynaud's phenomenon symptom. Reference ranges for creatinine are 60–115  $\mu\text{mol/L}$ , CRP < 10  $\text{mg/L}$ , and sIL2r < 600  $\text{U/mL}$ .